Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This dual-pathway approach produces body composition changes that are faster and more complete than either peptide achieves independently
3 The takeaway: Behavior change matters to people on GLP-1s, and the Noom app continues to be associated with stronger real-world GLP-1 outcomes Taken together, these findings tell a clear story: people who pair GLP-1 medication with consistent engagement in the Noom app see more success at weight loss, and, independently, they stay with the program longer
[1] [2] Common examples include semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda)
Consistent with this, co-administration of the GLP-2R agonist h(Gly 2 )GLP-2 and exendin-4 increases small intestinal weight and length to a greater extent compared to the agonists administered alone (Koehler et al., 2015)
